Literature DB >> 21925773

Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors.

Qiang Huang1, Maofa Zheng, Shuangshuang Yang, Chunxiang Kuang, Cunjing Yu, Qing Yang.   

Abstract

Previously, we have reported the design and synthesis of 4-aryl-1H-1,2,3-triazoles as inhibitors of indoleamine 2,3-dioxygenase (IDO), a promising therapeutic target of cancer. Here, we present the structure-activity relationship and enzyme kinetic studies on a series of 4-aryl-1H-1,2,3-triazoles. Three compounds (1, 6, 8) were found to possess more IDO inhibitory potency than the most commonly used 1-methyltryptophan. The results from the structure-activity relationship and molecular docking studies indicated that an electron-withdrawing group with low steric hindrance near the NH group of triazoles was necessary for the IDO inhibition.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925773     DOI: 10.1016/j.ejmech.2011.08.044

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  14 in total

1.  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

Authors:  William P Malachowski; Maria Winters; James B DuHadaway; Ariel Lewis-Ballester; Shorouk Badir; Jenny Wai; Maisha Rahman; Eesha Sheikh; Judith M LaLonde; Syun-Ru Yeh; George C Prendergast; Alexander J Muller
Journal:  Eur J Med Chem       Date:  2015-12-17       Impact factor: 6.514

Review 2.  Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Xiu-Xiu Wang; Si-Yu Sun; Qing-Qing Dong; Xiao-Xiang Wu; Wei Tang; Ya-Qun Xing
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

3.  Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors.

Authors:  Subhankar Panda; Ashalata Roy; Suman Jyoti Deka; Vishal Trivedi; Debasis Manna
Journal:  ACS Med Chem Lett       Date:  2016-10-15       Impact factor: 4.345

4.  Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy.

Authors:  Daojing Yan; Jiakun Xu; Xiang Wang; Jiaxing Zhang; Gang Zhao; Yingwu Lin; Xiangshi Tan
Journal:  Int J Mol Sci       Date:  2022-04-23       Impact factor: 6.208

5.  Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1.

Authors:  Saurav Paul; Ashalata Roy; Suman Jyoti Deka; Subhankar Panda; Gopal Narayan Srivastava; Vishal Trivedi; Debasis Manna
Journal:  Medchemcomm       Date:  2017-06-20       Impact factor: 3.597

6.  Synthesis of Tris-Heterocycles via a Cascade IMCR/Aza Diels-Alder + CuAAC Strategy.

Authors:  Manuel A Rentería-Gómez; Alejandro Islas-Jácome; Shrikant G Pharande; David A Vosburg; Rocío Gámez-Montaño
Journal:  Front Chem       Date:  2019-08-06       Impact factor: 5.221

7.  Effects of various phytochemicals on indoleamine 2,3-dioxygenase 1 activity: galanal is a novel, competitive inhibitor of the enzyme.

Authors:  Rie Yamamoto; Yasuko Yamamoto; Shinjiro Imai; Ryuta Fukutomi; Yoshio Ozawa; Masako Abe; Yushi Matuo; Kuniaki Saito
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

8.  Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure.

Authors:  Francesco Antonio Greco; Answald Bournique; Alice Coletti; Chiara Custodi; Daniela Dolciami; Andrea Carotti; Antonio Macchiarulo
Journal:  Mol Inform       Date:  2016-07-19       Impact factor: 3.353

Review 9.  Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry.

Authors:  Alice Coletti; Francesco Antonio Greco; Daniela Dolciami; Emidio Camaioni; Roccaldo Sardella; Maria Teresa Pallotta; Claudia Volpi; Ciriana Orabona; Ursula Grohmann; Antonio Macchiarulo
Journal:  Medchemcomm       Date:  2017-05-16       Impact factor: 3.597

10.  The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells.

Authors:  Holly C Lewis; Raghavan Chinnadurai; Steven E Bosinger; Jacques Galipeau
Journal:  Oncotarget       Date:  2017-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.